Bruker Corporation (NASDAQ:BRKR) Sees Significant Decrease in Short Interest

Key Points

• Bruker Corporation experienced a significant 28.7% decrease in short interest in August, with current short interest totaling 6,650,000 shares, representing 6.5% of the stock.
• The company reported Q2 earnings of $0.32 EPS, falling short of analysts' expectations, and a revenue of $797.40 million, slightly down from the previous year's $800 million.
• Bruker declared a dividend of $0.05 per share, to be paid on October 3rd, resulting in an annual yield of 0.6% and a payout ratio of 38.46%.

Bruker Corporation (NASDAQ:BRKR - Get Free Report) was the recipient of a significant drop in short interest in August. As of August 15th, there was short interest totaling 6,650,000 shares, adropof28.7% from the July 31st total of 9,330,000 shares. Currently,6.5% of the shares of the stock are short sold. Based on an average trading volume of 2,860,000 shares, the days-to-cover ratio is presently 2.3 days. Based on an average trading volume of 2,860,000 shares, the days-to-cover ratio is presently 2.3 days. Currently,6.5% of the shares of the stock are short sold.

Bruker Stock Performance

Bruker stock opened at $30.83 on Monday. The company has a current ratio of 1.61, a quick ratio of 0.70 and a debt-to-equity ratio of 1.31. The firm has a market cap of $4.68 billion, a P/E ratio of 59.29, a P/E/G ratio of 3.84 and a beta of 1.22. Bruker has a 1-year low of $28.53 and a 1-year high of $72.94. The firm has a 50-day moving average of $37.12 and a 200-day moving average of $39.51.

Bruker (NASDAQ:BRKR - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The medical research company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). Bruker had a net margin of 2.31% and a return on equity of 17.89%. The business had revenue of $797.40 million for the quarter, compared to the consensus estimate of $811.17 million. During the same period in the previous year, the company earned $0.52 EPS. The company's revenue for the quarter was down .4% on a year-over-year basis. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. Sell-side analysts expect that Bruker will post 2.69 EPS for the current year.

Bruker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 3rd. Investors of record on Tuesday, September 23rd will be paid a $0.05 dividend. The ex-dividend date of this dividend is Tuesday, September 23rd. This represents a $0.20 dividend on an annualized basis and a yield of 0.6%. Bruker's dividend payout ratio (DPR) is presently 38.46%.

Institutional Trading of Bruker

Large investors have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC raised its holdings in Bruker by 377.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company's stock worth $25,000 after purchasing an additional 487 shares in the last quarter. Pinnacle Bancorp Inc. purchased a new position in shares of Bruker during the first quarter valued at about $29,000. Allworth Financial LP increased its position in shares of Bruker by 92.4% during the first quarter. Allworth Financial LP now owns 758 shares of the medical research company's stock valued at $30,000 after buying an additional 364 shares during the period. Huntington National Bank raised its stake in Bruker by 750.0% in the second quarter. Huntington National Bank now owns 731 shares of the medical research company's stock worth $30,000 after buying an additional 645 shares in the last quarter. Finally, Spire Wealth Management purchased a new stake in Bruker in the second quarter worth about $32,000. Institutional investors own 79.52% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Bank of America reduced their target price on shares of Bruker from $61.00 to $50.00 and set a "buy" rating on the stock in a report on Thursday, June 26th. Citigroup reduced their price objective on Bruker from $40.00 to $38.00 and set a "neutral" rating on the stock in a research note on Monday, August 4th. Jefferies Financial Group set a $60.00 price objective on Bruker and gave the stock a "buy" rating in a report on Monday, August 4th. Stifel Nicolaus set a $40.00 target price on Bruker and gave the company a "hold" rating in a report on Tuesday, August 5th. Finally, Wells Fargo & Company reduced their price target on Bruker from $60.00 to $50.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 5th. Five investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $51.30.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.